Clinical Trial

A Study to Evaluate Pumitamig Versus Durvalumab Following Concurrent Chemoradiation Therapy in Participants With Unresectable Stage III Non-small Cell Lung Cancer (NSCLC) (ROSETTA Lung-201)

Recruiting Phase 3
View on ClinicalTrials.gov →
Summary
A study to evaluate Pumitamig versus Durvalumab following concurrent chemoradiation therapy in participants with unresectable stage III Non-small Cell Lung Cancer (NSCLC)
Protocol Amendment History 9 amendments
This ClinicalTrials.gov record has been amended 9 times since 2026-01-21; most recent amendment 2026-07-17.
Status change: Not Yet Recruiting → Recruiting 2026-03-24
Trial Details
NCT Number NCT07361497
Lead Sponsor Bristol-Myers Squibb
Collaborators: BioNTech SE
Conditions Non-small Cell Lung Cancer (NSCLC)
Enrollment 850 participants
Start Date 2026-03-16
Primary Completion 2030-09-18 (estimated)
Study Completion 2033-12-31 (estimated)
Updated on ClinicalTrials.gov 2026-08-10